human
immunodefici
viru
hiv
infect
individu
increas
risk
sever
diseas
numer
infect
includ
recurr
respiratori
infect
although
overal
mortal
associ
pandem
influenza
viru
infect
consid
low
individu
risk
complic
identifi
immunocompromis
individu
includ
hivinfect
prevent
strategi
vaccin
recommend
hivinfect
individu
follow
recommend
healthi
individu
howev
uncertainti
regard
best
vaccin
schedul
patient
impair
immun
although
studi
explor
modifi
vaccin
regimen
popul
studi
need
evalu
vaccin
dosag
number
applic
novel
adjuv
brazil
serious
affect
influenzalik
sever
acut
respiratori
infect
case
laboratoryconfirm
case
occur
winter
season
aim
studi
measur
seroconvers
singl
versu
doubl
dose
adjuv
vaccin
hivinfect
particip
compar
hivneg
control
addit
persist
antibodi
level
evalu
followup
six
month
open
label
random
phaseii
trial
compar
safeti
immunogen
persist
immun
respons
follow
vaccin
hivinfect
patient
random
receiv
singl
hemagglutinin
doubl
hemagglutinin
dose
adjuv
vaccin
day
apart
hivinfect
patient
also
compar
nonrandom
control
receiv
singl
dose
primari
endpoint
studi
seroconvers
defin
serum
titer
vaccin
baselin
titer
least
increas
vaccin
measur
hemagglutin
inhibit
assay
hai
describ
seroprotect
defin
serum
titer
hivinfect
patient
receiv
care
hivaid
clinic
evandro
chaga
clinic
research
institut
fiocruz
approach
studi
particip
control
neg
hiv
rapid
test
result
screen
visit
patient
control
enrol
simultan
march
august
estim
sampl
size
defin
higher
valu
obtain
two
differ
criteria
noninferior
limit
seroconvers
compar
two
group
hivinfect
patient
percentag
point
differ
seroconvers
compar
hivneg
control
assum
seroconvers
studi
protocol
approv
research
ethic
committe
instituto
de
pesquisa
evandro
chaga
regist
clinic
trial
network
particip
provid
written
inform
consent
inclus
criteria
particip
age
year
main
exclus
criteria
receipt
anoth
investig
vaccin
drug
past
week
season
influenza
vaccin
previou
month
previou
anaphylaxi
seriou
reaction
vaccin
hypersensit
egg
chicken
protein
ovalbumin
neurolog
ill
acut
ill
day
enrol
pregnanc
breastfeed
split
inactiv
influenza
viru
contain
antigen
equival
vlike
strain
hemagglutinin
adjuv
gsk
use
patient
receiv
two
singl
antigen
two
doubl
dose
antigen
accord
random
scheme
studi
subject
random
mean
comput
gener
random
number
function
ranuni
sa
version
previous
assign
one
vaccin
scheme
statistician
random
use
permut
block
size
alloc
ratio
stratifi
count
cell
cell
protocol
amend
earli
field
work
discontinu
stratif
count
elig
particip
less
cell
per
assign
print
place
opaqu
envelop
seal
sequenti
number
whole
process
conceal
studi
team
sign
consent
form
next
envelop
sequenc
open
vaccin
scheme
disclos
studi
team
particip
vial
vaccin
use
one
particip
blood
sampl
collect
baselin
day
month
baselin
demograph
clinic
data
retriev
medic
record
rna
viral
load
versant
rna
assay
siemen
h
diagnost
il
usa
cell
count
bd
bioscienc
ca
usa
measur
baselin
day
baselin
surveil
influenzalik
ill
ili
start
studi
enrol
continu
follow
month
advers
event
assess
clinic
vaccin
phone
contact
hour
vaccin
person
vaccin
follow
whorecommend
protocol
perform
hai
assay
brief
serum
sampl
treat
receptordestroy
enzym
denkaseiken
japan
incub
four
hemagglutin
unit
hour
guinea
pig
red
blood
cell
ad
well
final
concentr
incub
hour
hai
read
result
express
reciproc
highest
dilut
inhibit
hemagglutin
hai
titer
consid
valu
calcul
purpos
nasopharyng
dacronswab
specimen
collect
particip
display
acut
respiratori
infect
place
onto
transport
medium
hank
solut
uml
penicillin
streptomycin
rna
clinic
sampl
extract
qiamp
viral
rna
mini
kit
qiagen
germani
test
presenc
season
whocdcrecommend
rrtpcr
real
time
rtpcr
perform
detect
follow
agent
subtyp
influenza
influenza
b
coronaviru
e
parainfluenza
metapneumoviru
parechoviru
rhinoviru
rsv
ab
bocaviru
adenoviru
enteroviru
fasttrack
diagnosi
luxembourg
luxembourg
statist
analys
perform
sa
cari
nc
usa
sa
institut
inc
spss
statist
releas
version
spss
inc
differ
confid
limit
proport
logarithm
antibodi
titer
doubl
dose
singl
dose
calcul
noninferior
limit
seroconvers
ratio
geometr
mean
titer
respect
statist
signific
differ
proport
assess
use
chisquar
test
comparison
mean
base
ttest
cumul
curv
antibodi
titer
compar
across
group
use
logrank
test
test
use
confid
limit
logist
regress
use
adjust
degre
associ
vaccin
scheme
seroconvers
day
baselin
demograph
clinic
factor
likewis
associ
antibodi
titer
relev
covari
explor
multipl
regress
model
twohundr
fifti
six
patient
random
receiv
two
singl
dose
receiv
two
doubl
dose
figur
patient
receiv
first
dose
vaccin
receiv
second
dose
withdraw
due
clinic
condit
detect
recruit
patient
miss
appoint
patient
among
control
miss
appoint
healthunrel
reason
patient
show
balanc
distribut
baselin
demograph
clinic
variabl
tabl
includ
prevaccin
antibodi
level
tabl
figur
day
plot
patient
predominantli
middleag
adult
men
wherea
among
control
younger
femal
prevail
enrol
almost
patient
haart
cell
count
surpass
approxim
undetect
hiv
rna
viral
load
tabl
approxim
half
patient
nadir
cell
count
baselin
patient
control
seroprotect
antibodi
level
ie
tabl
antibodi
level
proport
seroprotect
slightli
higher
subgroup
age
year
twenti
one
day
first
dose
proport
seroprotect
antibodi
level
geometr
mean
titer
gmt
rose
substanti
group
tabl
figur
day
among
patient
rise
impli
approxim
seroconvers
slightli
higher
among
recipi
doubl
dose
tabl
seroconvers
antibodi
level
much
higher
among
control
despit
modest
seroprotect
tabl
figur
day
group
seroconvers
rate
gmt
follow
first
dose
somewhat
higher
among
particip
age
year
second
dose
patient
experienc
substanti
rise
seroprotect
seroconvers
exceed
control
antibodi
level
among
receiv
doubl
dose
far
exceed
control
tabl
figur
day
particip
age
year
show
higher
seroconvers
rate
higher
gmt
compar
younger
particip
particularli
among
control
patient
receiv
doubl
dose
six
month
day
recruit
seroprotect
rate
among
patient
decreas
slightli
gmt
fell
half
level
day
among
control
seroprotect
rate
increas
substanti
gmt
decreas
compar
day
level
tabl
seroconvers
rate
gmt
consist
lower
singl
dose
group
time
confid
limit
differ
proport
seroconvers
gmt
ratio
provid
evid
reject
hypothesi
inferior
singl
dose
tabl
fact
superior
two
doubl
dose
suggest
gmt
exceed
upper
confid
limit
gmt
two
singl
dose
tabl
statist
signific
logrank
p
cumul
curv
doubl
singl
dose
figur
day
compar
hivneg
control
seroconvers
second
dose
occur
time
often
among
two
doubl
dose
recipi
associ
lack
statist
signific
tabl
older
age
year
also
increas
odd
seroconvers
statist
signific
predictor
adjust
covari
consist
differ
antibodi
titer
hivinfect
group
hivneg
control
day
vaccin
adjust
antibodi
titer
vaccin
age
statist
signific
data
shown
among
patient
seroconvers
provid
two
doubl
dose
higher
age
women
nadir
cell
count
undetect
viral
load
haart
tabl
seroconvers
among
women
nadir
cell
count
significantli
higher
two
doubl
dose
use
averag
reduct
cell
count
day
first
dose
pronounc
among
particip
receiv
two
doubl
dose
differ
statist
signific
clinic
relev
tabl
second
dose
small
averag
increas
cell
count
observ
singl
dose
group
doubl
dose
group
show
neglig
differ
group
small
similar
percentag
patient
show
increas
decreas
hiv
viral
load
frequent
local
advers
reaction
pain
report
first
dose
patient
receiv
singl
doubl
dose
respect
figur
group
second
dose
particip
report
pain
eightysix
percent
control
also
report
pain
frequent
system
advers
event
fever
report
first
dose
patient
receiv
singl
doubl
dose
respect
total
particip
present
ili
within
month
first
vaccin
dose
ili
event
patient
receiv
singl
doubl
dose
respect
ili
event
among
control
nasopharyng
sampl
collect
particip
tabl
ili
identifi
six
patient
season
influenza
patient
influenza
b
patient
virus
detect
line
influenza
season
occur
period
studi
note
one
patient
receiv
doubl
dose
coinfect
rhinoviru
influenza
b
knowledg
first
random
control
trial
design
evalu
efficaci
sustain
protect
titer
adjuv
vaccin
hivinfect
adult
latin
america
april
decemb
fallwint
southern
hemispher
viru
circul
brazil
end
death
report
intern
local
guidelin
recommend
priorit
vaccin
hivinfect
individu
vaccin
carri
singl
dose
follow
schedul
hivneg
individu
howev
seroconvers
influenza
vaccin
among
hivinfect
individu
shown
lower
observ
gener
popul
light
scenario
evalu
altern
vaccin
scheme
hivinfect
individu
hivinfect
popul
seroconvers
increas
first
dose
second
dose
vaccin
use
singl
doubl
dose
respect
similarli
seroprotect
increas
first
dose
second
dose
vaccin
scheme
percentag
seroconvers
compar
found
soonawala
et
al
smaller
nonrandom
studi
lower
seroconvers
found
bickel
launay
enrol
asymptomat
hivinfect
adult
germani
franc
studi
patient
characterist
compar
studi
popul
ie
high
mean
baselin
cell
count
contrast
although
haart
use
almost
patient
undetect
viral
load
observ
roughli
previou
aidsdefin
ill
comparison
studi
cite
studi
popul
advanc
diseas
addit
differ
pattern
viru
circul
northern
southern
hemispher
may
hamper
comparison
seroconvers
result
other
studi
northern
hemispher
enrol
patient
novemb
decemb
overlap
second
wave
pandem
locat
sinc
circul
vaccin
strain
viru
virtual
subclin
infect
circul
virus
may
boost
immun
respons
individu
northern
hemispher
lead
higher
ha
titer
brazil
contrast
vaccin
carri
prior
southern
hemispher
winter
circul
brazil
decreas
significantli
compar
fact
brazilian
surveil
system
detect
influenza
b
circul
concomit
circul
thu
minim
circul
studi
consequ
immun
boost
due
viru
circul
unlik
studi
one
third
hivinfect
particip
seroprotect
antibodi
titer
baselin
valu
higher
observ
studi
conduct
northern
hemispher
corrobor
high
circul
brazil
result
show
level
protect
titer
among
seroconvert
six
month
vaccin
lower
patient
compar
control
result
consist
report
decreas
sustain
antibodi
respons
among
hivinfect
adult
data
durabl
influenza
antibodi
season
vaccin
gener
popul
suggest
protect
last
least
one
year
hivinfect
popul
limit
data
avail
studi
report
followup
sustain
antibodi
respons
import
sinc
influenza
season
often
span
estim
six
month
furthermor
pandem
influenza
infect
may
occur
nonseason
month
necessit
prolong
immun
studi
show
higher
proport
patient
receiv
two
doubl
dose
abl
sustain
protect
antibodi
respons
six
month
thu
data
suggest
modifi
vaccin
schedul
may
confer
higher
sustain
seroprotect
find
import
implic
hiv
care
public
health
polici
result
suggest
two
doubl
dose
adjuv
vaccin
elicit
significantli
higher
seroconvers
among
women
compar
two
singl
dose
histor
women
underrepres
hiv
clinic
trial
antiretrovir
therapi
well
therapeut
trial
area
cardiovascular
lung
cancer
research
current
increas
awar
need
repres
inclus
women
hiv
clinic
trial
one
third
particip
women
higher
percentag
compar
trial
previous
publish
vaccin
among
hivinfect
individu
like
studi
first
evalu
potenti
sexbas
differ
seroconvers
function
vaccin
scheme
thu
uniqu
find
studi
increas
seroconvers
among
particip
age
year
might
due
previou
exposur
low
glycosyl
viru
lifetim
seri
public
describ
similar
hemagglutinin
virus
low
glycosyl
although
glycosyl
virus
also
similar
agent
virus
circul
heavili
glycosyl
therefor
previou
exposur
virus
could
confer
crossimmun
consequ
possibl
vaccin
could
boost
exist
immun
low
glycosyl
hemagglutinin
like
present
particip
age
year
six
month
followup
ili
laboratori
diagnos
fifteen
particip
least
one
respiratori
viru
detect
case
found
vaccin
well
toler
studi
popul
local
pain
fever
frequent
local
system
advers
event
frequent
seen
among
patient
random
doubl
dose
arm
regard
impact
vaccin
hiv
viral
load
cell
count
result
corrobor
recent
find
clinic
meaning
effect
vaccin
cell
count
hiv
viral
load
also
find
associ
seroconvers
baselin
cell
count
result
show
doubl
dose
elicit
signific
higher
seroconvers
among
patient
nadir
cell
count
limit
studi
acknowledg
singlecent
studi
entri
criteria
limit
patient
without
current
comorbid
conduct
singl
season
evalu
well
control
cohort
hivinfect
individu
thu
could
determin
impact
current
sever
immunosuppress
vaccin
respons
howev
studi
advantag
concurr
evalu
group
hivuninfect
control
signific
proport
women
studi
provid
compel
evid
need
differ
vaccin
scheme
hivinfect
individu
higher
vaccin
dose
would
provid
addit
benefit
women
histori
advanc
immunodefici
summari
result
show
patient
achiev
level
seroconvers
compar
control
two
dose
adjuv
vaccin
interv
dose
import
induc
higher
seroconvers
vaccin
hemagglutinin
dosag
patient
nadir
cell
count
women
show
improv
seroconvers
doubl
dose
also
provid
sustain
seroprotect
find
contribut
plan
next
year
influenza
vaccin
campaign
also
suggest
vaccin
use
current
recommend
dosag
schedul
signific
proport
individu
remain
vulner
influenza
